Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
33,560
archived clinical trials in
Neurology

Study of Pharmacokinetics, Safety, Efficacy, and Tolerability of Memantine in Children With Autism
An Open-label (Part One) and a Randomized, Double-blind, Placebo-Controlled (Part Two) Study of the Pharmacokinetics, Safety, Efficacy, and Tolerability of Memantine in Pediatric Patients With Autism
Status: Archived
Lincoln Medical Center
mi
from
Lincoln, NE
Study of Pharmacokinetics, Safety, Efficacy, and Tolerability of Memantine in Children With Autism
An Open-label (Part One) and a Randomized, Double-blind, Placebo-Controlled (Part Two) Study of the Pharmacokinetics, Safety, Efficacy, and Tolerability of Memantine in Pediatric Patients With Autism
Status: Archived
Updated: 1/1/1970
Lincoln Medical Center
mi
from
Lincoln, NE
Study of Pharmacokinetics, Safety, Efficacy, and Tolerability of Memantine in Children With Autism
An Open-label (Part One) and a Randomized, Double-blind, Placebo-Controlled (Part Two) Study of the Pharmacokinetics, Safety, Efficacy, and Tolerability of Memantine in Pediatric Patients With Autism
Status: Archived
Forest Investigative Site
mi
from
Sacramento, CA
Study of Pharmacokinetics, Safety, Efficacy, and Tolerability of Memantine in Children With Autism
An Open-label (Part One) and a Randomized, Double-blind, Placebo-Controlled (Part Two) Study of the Pharmacokinetics, Safety, Efficacy, and Tolerability of Memantine in Pediatric Patients With Autism
Status: Archived
Updated: 1/1/1970
Forest Investigative Site
mi
from
Sacramento, CA
Study of Pharmacokinetics, Safety, Efficacy, and Tolerability of Memantine in Children With Autism
An Open-label (Part One) and a Randomized, Double-blind, Placebo-Controlled (Part Two) Study of the Pharmacokinetics, Safety, Efficacy, and Tolerability of Memantine in Pediatric Patients With Autism
Status: Archived
Forest Investigative Site 021
mi
from
San Francisco, CA
Study of Pharmacokinetics, Safety, Efficacy, and Tolerability of Memantine in Children With Autism
An Open-label (Part One) and a Randomized, Double-blind, Placebo-Controlled (Part Two) Study of the Pharmacokinetics, Safety, Efficacy, and Tolerability of Memantine in Pediatric Patients With Autism
Status: Archived
Updated: 1/1/1970
Forest Investigative Site 021
mi
from
San Francisco, CA
Study of Pharmacokinetics, Safety, Efficacy, and Tolerability of Memantine in Children With Autism
An Open-label (Part One) and a Randomized, Double-blind, Placebo-Controlled (Part Two) Study of the Pharmacokinetics, Safety, Efficacy, and Tolerability of Memantine in Pediatric Patients With Autism
Status: Archived
Forest Investigative Site
mi
from
Boca Raton, FL
Study of Pharmacokinetics, Safety, Efficacy, and Tolerability of Memantine in Children With Autism
An Open-label (Part One) and a Randomized, Double-blind, Placebo-Controlled (Part Two) Study of the Pharmacokinetics, Safety, Efficacy, and Tolerability of Memantine in Pediatric Patients With Autism
Status: Archived
Updated: 1/1/1970
Forest Investigative Site
mi
from
Boca Raton, FL
Study of Pharmacokinetics, Safety, Efficacy, and Tolerability of Memantine in Children With Autism
An Open-label (Part One) and a Randomized, Double-blind, Placebo-Controlled (Part Two) Study of the Pharmacokinetics, Safety, Efficacy, and Tolerability of Memantine in Pediatric Patients With Autism
Status: Archived
Forest Investigative Site
mi
from
Chicago, IL
Study of Pharmacokinetics, Safety, Efficacy, and Tolerability of Memantine in Children With Autism
An Open-label (Part One) and a Randomized, Double-blind, Placebo-Controlled (Part Two) Study of the Pharmacokinetics, Safety, Efficacy, and Tolerability of Memantine in Pediatric Patients With Autism
Status: Archived
Updated: 1/1/1970
Forest Investigative Site
mi
from
Chicago, IL
Study of Pharmacokinetics, Safety, Efficacy, and Tolerability of Memantine in Children With Autism
An Open-label (Part One) and a Randomized, Double-blind, Placebo-Controlled (Part Two) Study of the Pharmacokinetics, Safety, Efficacy, and Tolerability of Memantine in Pediatric Patients With Autism
Status: Archived
University of Pittsburgh and University of Pittsburgh Medical Center
mi
from
Pittsburgh, PA
Study of Pharmacokinetics, Safety, Efficacy, and Tolerability of Memantine in Children With Autism
An Open-label (Part One) and a Randomized, Double-blind, Placebo-Controlled (Part Two) Study of the Pharmacokinetics, Safety, Efficacy, and Tolerability of Memantine in Pediatric Patients With Autism
Status: Archived
Updated: 1/1/1970
University of Pittsburgh and University of Pittsburgh Medical Center
mi
from
Pittsburgh, PA
Study of Pharmacokinetics, Safety, Efficacy, and Tolerability of Memantine in Children With Autism
An Open-label (Part One) and a Randomized, Double-blind, Placebo-Controlled (Part Two) Study of the Pharmacokinetics, Safety, Efficacy, and Tolerability of Memantine in Pediatric Patients With Autism
Status: Archived
Sheppard Pratt Health System
mi
from
Baltimore, MD
Study of Pharmacokinetics, Safety, Efficacy, and Tolerability of Memantine in Children With Autism
An Open-label (Part One) and a Randomized, Double-blind, Placebo-Controlled (Part Two) Study of the Pharmacokinetics, Safety, Efficacy, and Tolerability of Memantine in Pediatric Patients With Autism
Status: Archived
Updated: 1/1/1970
Sheppard Pratt Health System
mi
from
Baltimore, MD
Study of Pharmacokinetics, Safety, Efficacy, and Tolerability of Memantine in Children With Autism
An Open-label (Part One) and a Randomized, Double-blind, Placebo-Controlled (Part Two) Study of the Pharmacokinetics, Safety, Efficacy, and Tolerability of Memantine in Pediatric Patients With Autism
Status: Archived
Forest Investigative Site
mi
from
Manhasset, NY
Study of Pharmacokinetics, Safety, Efficacy, and Tolerability of Memantine in Children With Autism
An Open-label (Part One) and a Randomized, Double-blind, Placebo-Controlled (Part Two) Study of the Pharmacokinetics, Safety, Efficacy, and Tolerability of Memantine in Pediatric Patients With Autism
Status: Archived
Updated: 1/1/1970
Forest Investigative Site
mi
from
Manhasset, NY
Study of Pharmacokinetics, Safety, Efficacy, and Tolerability of Memantine in Children With Autism
An Open-label (Part One) and a Randomized, Double-blind, Placebo-Controlled (Part Two) Study of the Pharmacokinetics, Safety, Efficacy, and Tolerability of Memantine in Pediatric Patients With Autism
Status: Archived
Forest Investigative Site
mi
from
Cleveland, OH
Study of Pharmacokinetics, Safety, Efficacy, and Tolerability of Memantine in Children With Autism
An Open-label (Part One) and a Randomized, Double-blind, Placebo-Controlled (Part Two) Study of the Pharmacokinetics, Safety, Efficacy, and Tolerability of Memantine in Pediatric Patients With Autism
Status: Archived
Updated: 1/1/1970
Forest Investigative Site
mi
from
Cleveland, OH
Study of Pharmacokinetics, Safety, Efficacy, and Tolerability of Memantine in Children With Autism
An Open-label (Part One) and a Randomized, Double-blind, Placebo-Controlled (Part Two) Study of the Pharmacokinetics, Safety, Efficacy, and Tolerability of Memantine in Pediatric Patients With Autism
Status: Archived
Forest Investigative
mi
from
Enid, OK
Study of Pharmacokinetics, Safety, Efficacy, and Tolerability of Memantine in Children With Autism
An Open-label (Part One) and a Randomized, Double-blind, Placebo-Controlled (Part Two) Study of the Pharmacokinetics, Safety, Efficacy, and Tolerability of Memantine in Pediatric Patients With Autism
Status: Archived
Updated: 1/1/1970
Forest Investigative
mi
from
Enid, OK
Study of Pharmacokinetics, Safety, Efficacy, and Tolerability of Memantine in Children With Autism
An Open-label (Part One) and a Randomized, Double-blind, Placebo-Controlled (Part Two) Study of the Pharmacokinetics, Safety, Efficacy, and Tolerability of Memantine in Pediatric Patients With Autism
Status: Archived
Forest Investigative Site
mi
from
Oklahoma City, OK
Study of Pharmacokinetics, Safety, Efficacy, and Tolerability of Memantine in Children With Autism
An Open-label (Part One) and a Randomized, Double-blind, Placebo-Controlled (Part Two) Study of the Pharmacokinetics, Safety, Efficacy, and Tolerability of Memantine in Pediatric Patients With Autism
Status: Archived
Updated: 1/1/1970
Forest Investigative Site
mi
from
Oklahoma City, OK
Study of Pharmacokinetics, Safety, Efficacy, and Tolerability of Memantine in Children With Autism
An Open-label (Part One) and a Randomized, Double-blind, Placebo-Controlled (Part Two) Study of the Pharmacokinetics, Safety, Efficacy, and Tolerability of Memantine in Pediatric Patients With Autism
Status: Archived
Forest Investigative Site
mi
from
Pittsburgh, PA
Study of Pharmacokinetics, Safety, Efficacy, and Tolerability of Memantine in Children With Autism
An Open-label (Part One) and a Randomized, Double-blind, Placebo-Controlled (Part Two) Study of the Pharmacokinetics, Safety, Efficacy, and Tolerability of Memantine in Pediatric Patients With Autism
Status: Archived
Updated: 1/1/1970
Forest Investigative Site
mi
from
Pittsburgh, PA
Healthy Lifestyle in Adults With Attention Deficit Hyperactivity Disorder
Healthy Lifestyle in Adults With ADHD
Status: Archived
Massachusetts General Hospital
mi
from
Boston, MA
Healthy Lifestyle in Adults With Attention Deficit Hyperactivity Disorder
Healthy Lifestyle in Adults With ADHD
Status: Archived
Updated: 1/1/1970
Massachusetts General Hospital
mi
from
Boston, MA
Self Management in Urinary Catheter Users
Self-management of Urine Flow in Long-term Urinary Catheter Users
Status: Archived
Center for Home Care Policy & Research, Visiting Nurse Service of New York
mi
from
New York City, NY
Self Management in Urinary Catheter Users
Self-management of Urine Flow in Long-term Urinary Catheter Users
Status: Archived
Updated: 1/1/1970
Center for Home Care Policy & Research, Visiting Nurse Service of New York
mi
from
New York City, NY
Self Management in Urinary Catheter Users
Self-management of Urine Flow in Long-term Urinary Catheter Users
Status: Archived
Urinary of Rochester
mi
from
Rochester, NY
Self Management in Urinary Catheter Users
Self-management of Urine Flow in Long-term Urinary Catheter Users
Status: Archived
Updated: 1/1/1970
Urinary of Rochester
mi
from
Rochester, NY
Magnetoencephalography in Absence Seizures
Magnetoencephalography in Absence Seizures
Status: Archived
National Institutes of Health Clinical Center
mi
from
Bethesda, MD
Magnetoencephalography in Absence Seizures
Magnetoencephalography in Absence Seizures
Status: Archived
Updated: 1/1/1970
National Institutes of Health Clinical Center
mi
from
Bethesda, MD
Factor XI Levels in Acute Ischemic Stroke
Factor XI Levels in Acute Ischemic Stroke
Status: Archived
University Of Utah Hospital
mi
from
Salt Lake City, UT
Factor XI Levels in Acute Ischemic Stroke
Factor XI Levels in Acute Ischemic Stroke
Status: Archived
Updated: 1/1/1970
University Of Utah Hospital
mi
from
Salt Lake City, UT
Evaluation of Limb-Girdle Muscular Dystrophy
Evaluation of Limb-Girdle Muscular Dystrophy
Status: Archived
Children's Nutrition Research Center, Baylor College of Medicine
mi
from
Houston, TX
Evaluation of Limb-Girdle Muscular Dystrophy
Evaluation of Limb-Girdle Muscular Dystrophy
Status: Archived
Updated: 1/1/1970
Children's Nutrition Research Center, Baylor College of Medicine
mi
from
Houston, TX
Evaluation of Limb-Girdle Muscular Dystrophy
Evaluation of Limb-Girdle Muscular Dystrophy
Status: Archived
Carolinas Medical Center-Myers Park
mi
from
Charlotte, NC
Evaluation of Limb-Girdle Muscular Dystrophy
Evaluation of Limb-Girdle Muscular Dystrophy
Status: Archived
Updated: 1/1/1970
Carolinas Medical Center-Myers Park
mi
from
Charlotte, NC
Efficacy and Safety Study of DP-b99 in Treating Acute Ischemic Stroke
A Double Blind, Randomized, Placebo-controlled, Parallel Group, Multicenter Phase 3 Pivotal Study to Assess the Safety and Efficacy of 1mg/kg/Day Intravenous DP-b99 Over 4 Consecutive Days Versus Placebo When Initiated Within Nine Hours of Acute Ischemic Stroke Onset
Status: Archived
Research Center of Southern California
mi
from
Oceanside, CA
Efficacy and Safety Study of DP-b99 in Treating Acute Ischemic Stroke
A Double Blind, Randomized, Placebo-controlled, Parallel Group, Multicenter Phase 3 Pivotal Study to Assess the Safety and Efficacy of 1mg/kg/Day Intravenous DP-b99 Over 4 Consecutive Days Versus Placebo When Initiated Within Nine Hours of Acute Ischemic Stroke Onset
Status: Archived
Updated: 1/1/1970
Research Center of Southern California
mi
from
Oceanside, CA
Efficacy and Safety Study of DP-b99 in Treating Acute Ischemic Stroke
A Double Blind, Randomized, Placebo-controlled, Parallel Group, Multicenter Phase 3 Pivotal Study to Assess the Safety and Efficacy of 1mg/kg/Day Intravenous DP-b99 Over 4 Consecutive Days Versus Placebo When Initiated Within Nine Hours of Acute Ischemic Stroke Onset
Status: Archived
Associated Neurologists, P.C.
mi
from
Danbury, CT
Efficacy and Safety Study of DP-b99 in Treating Acute Ischemic Stroke
A Double Blind, Randomized, Placebo-controlled, Parallel Group, Multicenter Phase 3 Pivotal Study to Assess the Safety and Efficacy of 1mg/kg/Day Intravenous DP-b99 Over 4 Consecutive Days Versus Placebo When Initiated Within Nine Hours of Acute Ischemic Stroke Onset
Status: Archived
Updated: 1/1/1970
Associated Neurologists, P.C.
mi
from
Danbury, CT
Efficacy and Safety Study of DP-b99 in Treating Acute Ischemic Stroke
A Double Blind, Randomized, Placebo-controlled, Parallel Group, Multicenter Phase 3 Pivotal Study to Assess the Safety and Efficacy of 1mg/kg/Day Intravenous DP-b99 Over 4 Consecutive Days Versus Placebo When Initiated Within Nine Hours of Acute Ischemic Stroke Onset
Status: Archived
Bradenton Research Center
mi
from
Bradenton, FL
Efficacy and Safety Study of DP-b99 in Treating Acute Ischemic Stroke
A Double Blind, Randomized, Placebo-controlled, Parallel Group, Multicenter Phase 3 Pivotal Study to Assess the Safety and Efficacy of 1mg/kg/Day Intravenous DP-b99 Over 4 Consecutive Days Versus Placebo When Initiated Within Nine Hours of Acute Ischemic Stroke Onset
Status: Archived
Updated: 1/1/1970
Bradenton Research Center
mi
from
Bradenton, FL
Efficacy and Safety Study of DP-b99 in Treating Acute Ischemic Stroke
A Double Blind, Randomized, Placebo-controlled, Parallel Group, Multicenter Phase 3 Pivotal Study to Assess the Safety and Efficacy of 1mg/kg/Day Intravenous DP-b99 Over 4 Consecutive Days Versus Placebo When Initiated Within Nine Hours of Acute Ischemic Stroke Onset
Status: Archived
Halifax Health Medical Center
mi
from
Daytona Beach, FL
Efficacy and Safety Study of DP-b99 in Treating Acute Ischemic Stroke
A Double Blind, Randomized, Placebo-controlled, Parallel Group, Multicenter Phase 3 Pivotal Study to Assess the Safety and Efficacy of 1mg/kg/Day Intravenous DP-b99 Over 4 Consecutive Days Versus Placebo When Initiated Within Nine Hours of Acute Ischemic Stroke Onset
Status: Archived
Updated: 1/1/1970
Halifax Health Medical Center
mi
from
Daytona Beach, FL
Efficacy and Safety Study of DP-b99 in Treating Acute Ischemic Stroke
A Double Blind, Randomized, Placebo-controlled, Parallel Group, Multicenter Phase 3 Pivotal Study to Assess the Safety and Efficacy of 1mg/kg/Day Intravenous DP-b99 Over 4 Consecutive Days Versus Placebo When Initiated Within Nine Hours of Acute Ischemic Stroke Onset
Status: Archived
Neuroscience Research Institute/Dekalb Neurology
mi
from
Lawrenceville, GA
Efficacy and Safety Study of DP-b99 in Treating Acute Ischemic Stroke
A Double Blind, Randomized, Placebo-controlled, Parallel Group, Multicenter Phase 3 Pivotal Study to Assess the Safety and Efficacy of 1mg/kg/Day Intravenous DP-b99 Over 4 Consecutive Days Versus Placebo When Initiated Within Nine Hours of Acute Ischemic Stroke Onset
Status: Archived
Updated: 1/1/1970
Neuroscience Research Institute/Dekalb Neurology
mi
from
Lawrenceville, GA
Efficacy and Safety Study of DP-b99 in Treating Acute Ischemic Stroke
A Double Blind, Randomized, Placebo-controlled, Parallel Group, Multicenter Phase 3 Pivotal Study to Assess the Safety and Efficacy of 1mg/kg/Day Intravenous DP-b99 Over 4 Consecutive Days Versus Placebo When Initiated Within Nine Hours of Acute Ischemic Stroke Onset
Status: Archived
Memorial Health University Medical Center
mi
from
Savannah, GA
Efficacy and Safety Study of DP-b99 in Treating Acute Ischemic Stroke
A Double Blind, Randomized, Placebo-controlled, Parallel Group, Multicenter Phase 3 Pivotal Study to Assess the Safety and Efficacy of 1mg/kg/Day Intravenous DP-b99 Over 4 Consecutive Days Versus Placebo When Initiated Within Nine Hours of Acute Ischemic Stroke Onset
Status: Archived
Updated: 1/1/1970
Memorial Health University Medical Center
mi
from
Savannah, GA
Efficacy and Safety Study of DP-b99 in Treating Acute Ischemic Stroke
A Double Blind, Randomized, Placebo-controlled, Parallel Group, Multicenter Phase 3 Pivotal Study to Assess the Safety and Efficacy of 1mg/kg/Day Intravenous DP-b99 Over 4 Consecutive Days Versus Placebo When Initiated Within Nine Hours of Acute Ischemic Stroke Onset
Status: Archived
The University of Kentucky The Methodist Hospital
mi
from
Lexington, KY
Efficacy and Safety Study of DP-b99 in Treating Acute Ischemic Stroke
A Double Blind, Randomized, Placebo-controlled, Parallel Group, Multicenter Phase 3 Pivotal Study to Assess the Safety and Efficacy of 1mg/kg/Day Intravenous DP-b99 Over 4 Consecutive Days Versus Placebo When Initiated Within Nine Hours of Acute Ischemic Stroke Onset
Status: Archived
Updated: 1/1/1970
The University of Kentucky The Methodist Hospital
mi
from
Lexington, KY
Efficacy and Safety Study of DP-b99 in Treating Acute Ischemic Stroke
A Double Blind, Randomized, Placebo-controlled, Parallel Group, Multicenter Phase 3 Pivotal Study to Assess the Safety and Efficacy of 1mg/kg/Day Intravenous DP-b99 Over 4 Consecutive Days Versus Placebo When Initiated Within Nine Hours of Acute Ischemic Stroke Onset
Status: Archived
University of Louisville Hospital
mi
from
Louisville, KY
Efficacy and Safety Study of DP-b99 in Treating Acute Ischemic Stroke
A Double Blind, Randomized, Placebo-controlled, Parallel Group, Multicenter Phase 3 Pivotal Study to Assess the Safety and Efficacy of 1mg/kg/Day Intravenous DP-b99 Over 4 Consecutive Days Versus Placebo When Initiated Within Nine Hours of Acute Ischemic Stroke Onset
Status: Archived
Updated: 1/1/1970
University of Louisville Hospital
mi
from
Louisville, KY
Efficacy and Safety Study of DP-b99 in Treating Acute Ischemic Stroke
A Double Blind, Randomized, Placebo-controlled, Parallel Group, Multicenter Phase 3 Pivotal Study to Assess the Safety and Efficacy of 1mg/kg/Day Intravenous DP-b99 Over 4 Consecutive Days Versus Placebo When Initiated Within Nine Hours of Acute Ischemic Stroke Onset
Status: Archived
Tufts Clinical Pharmacology Study Unit
mi
from
Boston, MA
Efficacy and Safety Study of DP-b99 in Treating Acute Ischemic Stroke
A Double Blind, Randomized, Placebo-controlled, Parallel Group, Multicenter Phase 3 Pivotal Study to Assess the Safety and Efficacy of 1mg/kg/Day Intravenous DP-b99 Over 4 Consecutive Days Versus Placebo When Initiated Within Nine Hours of Acute Ischemic Stroke Onset
Status: Archived
Updated: 1/1/1970
Tufts Clinical Pharmacology Study Unit
mi
from
Boston, MA
Efficacy and Safety Study of DP-b99 in Treating Acute Ischemic Stroke
A Double Blind, Randomized, Placebo-controlled, Parallel Group, Multicenter Phase 3 Pivotal Study to Assess the Safety and Efficacy of 1mg/kg/Day Intravenous DP-b99 Over 4 Consecutive Days Versus Placebo When Initiated Within Nine Hours of Acute Ischemic Stroke Onset
Status: Archived
JFK Hospital
mi
from
Atlantis, FL
Efficacy and Safety Study of DP-b99 in Treating Acute Ischemic Stroke
A Double Blind, Randomized, Placebo-controlled, Parallel Group, Multicenter Phase 3 Pivotal Study to Assess the Safety and Efficacy of 1mg/kg/Day Intravenous DP-b99 Over 4 Consecutive Days Versus Placebo When Initiated Within Nine Hours of Acute Ischemic Stroke Onset
Status: Archived
Updated: 1/1/1970
JFK Hospital
mi
from
Atlantis, FL
Efficacy and Safety Study of DP-b99 in Treating Acute Ischemic Stroke
A Double Blind, Randomized, Placebo-controlled, Parallel Group, Multicenter Phase 3 Pivotal Study to Assess the Safety and Efficacy of 1mg/kg/Day Intravenous DP-b99 Over 4 Consecutive Days Versus Placebo When Initiated Within Nine Hours of Acute Ischemic Stroke Onset
Status: Archived
Capital Health
mi
from
Trenton, NJ
Efficacy and Safety Study of DP-b99 in Treating Acute Ischemic Stroke
A Double Blind, Randomized, Placebo-controlled, Parallel Group, Multicenter Phase 3 Pivotal Study to Assess the Safety and Efficacy of 1mg/kg/Day Intravenous DP-b99 Over 4 Consecutive Days Versus Placebo When Initiated Within Nine Hours of Acute Ischemic Stroke Onset
Status: Archived
Updated: 1/1/1970
Capital Health
mi
from
Trenton, NJ
Efficacy and Safety Study of DP-b99 in Treating Acute Ischemic Stroke
A Double Blind, Randomized, Placebo-controlled, Parallel Group, Multicenter Phase 3 Pivotal Study to Assess the Safety and Efficacy of 1mg/kg/Day Intravenous DP-b99 Over 4 Consecutive Days Versus Placebo When Initiated Within Nine Hours of Acute Ischemic Stroke Onset
Status: Archived
University of New Mexico
mi
from
Albuquerque, NM
Efficacy and Safety Study of DP-b99 in Treating Acute Ischemic Stroke
A Double Blind, Randomized, Placebo-controlled, Parallel Group, Multicenter Phase 3 Pivotal Study to Assess the Safety and Efficacy of 1mg/kg/Day Intravenous DP-b99 Over 4 Consecutive Days Versus Placebo When Initiated Within Nine Hours of Acute Ischemic Stroke Onset
Status: Archived
Updated: 1/1/1970
University of New Mexico
mi
from
Albuquerque, NM
Efficacy and Safety Study of DP-b99 in Treating Acute Ischemic Stroke
A Double Blind, Randomized, Placebo-controlled, Parallel Group, Multicenter Phase 3 Pivotal Study to Assess the Safety and Efficacy of 1mg/kg/Day Intravenous DP-b99 Over 4 Consecutive Days Versus Placebo When Initiated Within Nine Hours of Acute Ischemic Stroke Onset
Status: Archived
Mission Hospital, Inc
mi
from
Asheville, NC
Efficacy and Safety Study of DP-b99 in Treating Acute Ischemic Stroke
A Double Blind, Randomized, Placebo-controlled, Parallel Group, Multicenter Phase 3 Pivotal Study to Assess the Safety and Efficacy of 1mg/kg/Day Intravenous DP-b99 Over 4 Consecutive Days Versus Placebo When Initiated Within Nine Hours of Acute Ischemic Stroke Onset
Status: Archived
Updated: 1/1/1970
Mission Hospital, Inc
mi
from
Asheville, NC
Efficacy and Safety Study of DP-b99 in Treating Acute Ischemic Stroke
A Double Blind, Randomized, Placebo-controlled, Parallel Group, Multicenter Phase 3 Pivotal Study to Assess the Safety and Efficacy of 1mg/kg/Day Intravenous DP-b99 Over 4 Consecutive Days Versus Placebo When Initiated Within Nine Hours of Acute Ischemic Stroke Onset
Status: Archived
Presbitarian Hospital
mi
from
Charlotte, NC
Efficacy and Safety Study of DP-b99 in Treating Acute Ischemic Stroke
A Double Blind, Randomized, Placebo-controlled, Parallel Group, Multicenter Phase 3 Pivotal Study to Assess the Safety and Efficacy of 1mg/kg/Day Intravenous DP-b99 Over 4 Consecutive Days Versus Placebo When Initiated Within Nine Hours of Acute Ischemic Stroke Onset
Status: Archived
Updated: 1/1/1970
Presbitarian Hospital
mi
from
Charlotte, NC
Efficacy and Safety Study of DP-b99 in Treating Acute Ischemic Stroke
A Double Blind, Randomized, Placebo-controlled, Parallel Group, Multicenter Phase 3 Pivotal Study to Assess the Safety and Efficacy of 1mg/kg/Day Intravenous DP-b99 Over 4 Consecutive Days Versus Placebo When Initiated Within Nine Hours of Acute Ischemic Stroke Onset
Status: Archived
Metro Health Medical Center
mi
from
Cleveland, OH
Efficacy and Safety Study of DP-b99 in Treating Acute Ischemic Stroke
A Double Blind, Randomized, Placebo-controlled, Parallel Group, Multicenter Phase 3 Pivotal Study to Assess the Safety and Efficacy of 1mg/kg/Day Intravenous DP-b99 Over 4 Consecutive Days Versus Placebo When Initiated Within Nine Hours of Acute Ischemic Stroke Onset
Status: Archived
Updated: 1/1/1970
Metro Health Medical Center
mi
from
Cleveland, OH
Efficacy and Safety Study of DP-b99 in Treating Acute Ischemic Stroke
A Double Blind, Randomized, Placebo-controlled, Parallel Group, Multicenter Phase 3 Pivotal Study to Assess the Safety and Efficacy of 1mg/kg/Day Intravenous DP-b99 Over 4 Consecutive Days Versus Placebo When Initiated Within Nine Hours of Acute Ischemic Stroke Onset
Status: Archived
St. Elizabeths Medical Center
mi
from
Boston, MA
Efficacy and Safety Study of DP-b99 in Treating Acute Ischemic Stroke
A Double Blind, Randomized, Placebo-controlled, Parallel Group, Multicenter Phase 3 Pivotal Study to Assess the Safety and Efficacy of 1mg/kg/Day Intravenous DP-b99 Over 4 Consecutive Days Versus Placebo When Initiated Within Nine Hours of Acute Ischemic Stroke Onset
Status: Archived
Updated: 1/1/1970
St. Elizabeths Medical Center
mi
from
Boston, MA
Efficacy and Safety Study of DP-b99 in Treating Acute Ischemic Stroke
A Double Blind, Randomized, Placebo-controlled, Parallel Group, Multicenter Phase 3 Pivotal Study to Assess the Safety and Efficacy of 1mg/kg/Day Intravenous DP-b99 Over 4 Consecutive Days Versus Placebo When Initiated Within Nine Hours of Acute Ischemic Stroke Onset
Status: Archived
Legacy Meridian Park Medical Center
mi
from
Tualatin, OR
Efficacy and Safety Study of DP-b99 in Treating Acute Ischemic Stroke
A Double Blind, Randomized, Placebo-controlled, Parallel Group, Multicenter Phase 3 Pivotal Study to Assess the Safety and Efficacy of 1mg/kg/Day Intravenous DP-b99 Over 4 Consecutive Days Versus Placebo When Initiated Within Nine Hours of Acute Ischemic Stroke Onset
Status: Archived
Updated: 1/1/1970
Legacy Meridian Park Medical Center
mi
from
Tualatin, OR
Efficacy and Safety Study of DP-b99 in Treating Acute Ischemic Stroke
A Double Blind, Randomized, Placebo-controlled, Parallel Group, Multicenter Phase 3 Pivotal Study to Assess the Safety and Efficacy of 1mg/kg/Day Intravenous DP-b99 Over 4 Consecutive Days Versus Placebo When Initiated Within Nine Hours of Acute Ischemic Stroke Onset
Status: Archived
Lehigh Valley Hospital Mental Health Clinic
mi
from
Allentown, PA
Efficacy and Safety Study of DP-b99 in Treating Acute Ischemic Stroke
A Double Blind, Randomized, Placebo-controlled, Parallel Group, Multicenter Phase 3 Pivotal Study to Assess the Safety and Efficacy of 1mg/kg/Day Intravenous DP-b99 Over 4 Consecutive Days Versus Placebo When Initiated Within Nine Hours of Acute Ischemic Stroke Onset
Status: Archived
Updated: 1/1/1970
Lehigh Valley Hospital Mental Health Clinic
mi
from
Allentown, PA
Efficacy and Safety Study of DP-b99 in Treating Acute Ischemic Stroke
A Double Blind, Randomized, Placebo-controlled, Parallel Group, Multicenter Phase 3 Pivotal Study to Assess the Safety and Efficacy of 1mg/kg/Day Intravenous DP-b99 Over 4 Consecutive Days Versus Placebo When Initiated Within Nine Hours of Acute Ischemic Stroke Onset
Status: Archived
Thomas Jefferson Hospital
mi
from
Philadelphia, PA
Efficacy and Safety Study of DP-b99 in Treating Acute Ischemic Stroke
A Double Blind, Randomized, Placebo-controlled, Parallel Group, Multicenter Phase 3 Pivotal Study to Assess the Safety and Efficacy of 1mg/kg/Day Intravenous DP-b99 Over 4 Consecutive Days Versus Placebo When Initiated Within Nine Hours of Acute Ischemic Stroke Onset
Status: Archived
Updated: 1/1/1970
Thomas Jefferson Hospital
mi
from
Philadelphia, PA
Efficacy and Safety Study of DP-b99 in Treating Acute Ischemic Stroke
A Double Blind, Randomized, Placebo-controlled, Parallel Group, Multicenter Phase 3 Pivotal Study to Assess the Safety and Efficacy of 1mg/kg/Day Intravenous DP-b99 Over 4 Consecutive Days Versus Placebo When Initiated Within Nine Hours of Acute Ischemic Stroke Onset
Status: Archived
Vanderiblt University Medical Center
mi
from
Nashville, TN
Efficacy and Safety Study of DP-b99 in Treating Acute Ischemic Stroke
A Double Blind, Randomized, Placebo-controlled, Parallel Group, Multicenter Phase 3 Pivotal Study to Assess the Safety and Efficacy of 1mg/kg/Day Intravenous DP-b99 Over 4 Consecutive Days Versus Placebo When Initiated Within Nine Hours of Acute Ischemic Stroke Onset
Status: Archived
Updated: 1/1/1970
Vanderiblt University Medical Center
mi
from
Nashville, TN
Efficacy and Safety Study of DP-b99 in Treating Acute Ischemic Stroke
A Double Blind, Randomized, Placebo-controlled, Parallel Group, Multicenter Phase 3 Pivotal Study to Assess the Safety and Efficacy of 1mg/kg/Day Intravenous DP-b99 Over 4 Consecutive Days Versus Placebo When Initiated Within Nine Hours of Acute Ischemic Stroke Onset
Status: Archived
Houston Methodist Hospital
mi
from
Houston, TX
Efficacy and Safety Study of DP-b99 in Treating Acute Ischemic Stroke
A Double Blind, Randomized, Placebo-controlled, Parallel Group, Multicenter Phase 3 Pivotal Study to Assess the Safety and Efficacy of 1mg/kg/Day Intravenous DP-b99 Over 4 Consecutive Days Versus Placebo When Initiated Within Nine Hours of Acute Ischemic Stroke Onset
Status: Archived
Updated: 1/1/1970
Houston Methodist Hospital
mi
from
Houston, TX
Efficacy and Safety Study of DP-b99 in Treating Acute Ischemic Stroke
A Double Blind, Randomized, Placebo-controlled, Parallel Group, Multicenter Phase 3 Pivotal Study to Assess the Safety and Efficacy of 1mg/kg/Day Intravenous DP-b99 Over 4 Consecutive Days Versus Placebo When Initiated Within Nine Hours of Acute Ischemic Stroke Onset
Status: Archived
Carilion Clinic
mi
from
Roanoke, VA
Efficacy and Safety Study of DP-b99 in Treating Acute Ischemic Stroke
A Double Blind, Randomized, Placebo-controlled, Parallel Group, Multicenter Phase 3 Pivotal Study to Assess the Safety and Efficacy of 1mg/kg/Day Intravenous DP-b99 Over 4 Consecutive Days Versus Placebo When Initiated Within Nine Hours of Acute Ischemic Stroke Onset
Status: Archived
Updated: 1/1/1970
Carilion Clinic
mi
from
Roanoke, VA
Photosensitivity Proof of Concept Trial
Assessment of Marketed AEDs in the Human Photosensitivity Proof of Concept Trial
Status: Archived
Johns Hopkins University
mi
from
Baltimore, MD
Photosensitivity Proof of Concept Trial
Assessment of Marketed AEDs in the Human Photosensitivity Proof of Concept Trial
Status: Archived
Updated: 1/1/1970
Johns Hopkins University
mi
from
Baltimore, MD
Photosensitivity Proof of Concept Trial
Assessment of Marketed AEDs in the Human Photosensitivity Proof of Concept Trial
Status: Archived
New York University Langone Medical Center
mi
from
New York, NY
Photosensitivity Proof of Concept Trial
Assessment of Marketed AEDs in the Human Photosensitivity Proof of Concept Trial
Status: Archived
Updated: 1/1/1970
New York University Langone Medical Center
mi
from
New York, NY
Parent Training for Attention Deficit Hyperactivity Disorder (ADHD) Preschoolers
Home-Based Parent Training in ADHD Preschoolers
Status: Archived
New York University Langone Medical Center
mi
from
New York, NY
Parent Training for Attention Deficit Hyperactivity Disorder (ADHD) Preschoolers
Home-Based Parent Training in ADHD Preschoolers
Status: Archived
Updated: 1/1/1970
New York University Langone Medical Center
mi
from
New York, NY
A Study of Oxytocin in Children and Adolescents With Autistic Disorder
A Pilot Study of Oxytocin in Children and Adolescents With Autistic Disorder
Status: Archived
University of North Carolina Chapel Hill
mi
from
Chapel Hill, NC
A Study of Oxytocin in Children and Adolescents With Autistic Disorder
A Pilot Study of Oxytocin in Children and Adolescents With Autistic Disorder
Status: Archived
Updated: 1/1/1970
University of North Carolina Chapel Hill
mi
from
Chapel Hill, NC
Mental Practice in Chronic, Stroke-Induced Hemiparesis
Mental Practice in Chronic, Stroke-Induced Hemiparesis
Status: Archived
University of Cincinnati Medical Center
mi
from
Cincinnati, OH
Mental Practice in Chronic, Stroke-Induced Hemiparesis
Mental Practice in Chronic, Stroke-Induced Hemiparesis
Status: Archived
Updated: 1/1/1970
University of Cincinnati Medical Center
mi
from
Cincinnati, OH
Mental Practice in Chronic, Stroke-Induced Hemiparesis
Mental Practice in Chronic, Stroke-Induced Hemiparesis
Status: Archived
Metro Health Medical Center
mi
from
Cleveland, OH
Mental Practice in Chronic, Stroke-Induced Hemiparesis
Mental Practice in Chronic, Stroke-Induced Hemiparesis
Status: Archived
Updated: 1/1/1970
Metro Health Medical Center
mi
from
Cleveland, OH
Exercise Training Program for Cerebellar Ataxia
Exercise Training Program for Cerebellar Ataxia
Status: Archived
Kennedy Krieger Institute
mi
from
Baltimore, MD
Exercise Training Program for Cerebellar Ataxia
Exercise Training Program for Cerebellar Ataxia
Status: Archived
Updated: 1/1/1970
Kennedy Krieger Institute
mi
from
Baltimore, MD
Defining 31Phosphorous Magnetic Resonance Spectroscopy Characteristics in Patients With Mitochondrial Myopathy
Defining 31Phosphorous Magnetic Resonance Spectroscopy Characteristics of the Vastus Lateralis After Sub-maximal Exercise in Patients With Mitochondrial Myopathy
Status: Archived
Massachusetts General Hospital
mi
from
Boston, MA
Defining 31Phosphorous Magnetic Resonance Spectroscopy Characteristics in Patients With Mitochondrial Myopathy
Defining 31Phosphorous Magnetic Resonance Spectroscopy Characteristics of the Vastus Lateralis After Sub-maximal Exercise in Patients With Mitochondrial Myopathy
Status: Archived
Updated: 1/1/1970
Massachusetts General Hospital
mi
from
Boston, MA
MC5-A Scrambler Therapy in Reducing Peripheral Neuropathy Caused by Chemotherapy
Scrambler Therapy for the Treatment of Chemotherapy Induced Peripheral Neuropathy: An Evaluation of a Sham Procedure and Phase II Trial
Status: Archived
Mayo Clinic Rochester
mi
from
Rochester, MN
MC5-A Scrambler Therapy in Reducing Peripheral Neuropathy Caused by Chemotherapy
Scrambler Therapy for the Treatment of Chemotherapy Induced Peripheral Neuropathy: An Evaluation of a Sham Procedure and Phase II Trial
Status: Archived
Updated: 1/1/1970
Mayo Clinic Rochester
mi
from
Rochester, MN